These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 33799592)

  • 1. Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.
    Fairlie WD; Lee EF
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the B-cell lymphoma/leukemia 2 family in cancer.
    Davids MS; Letai A
    J Clin Oncol; 2012 Sep; 30(25):3127-35. PubMed ID: 22649144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BH3 mimetics to improve cancer therapy; mechanisms and examples.
    Zhang L; Ming L; Yu J
    Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
    Khaw SL; Huang DC; Roberts AW
    Pathology; 2011 Oct; 43(6):525-35. PubMed ID: 21881535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer.
    Shore GC; Viallet J
    Hematology Am Soc Hematol Educ Program; 2005; ():226-30. PubMed ID: 16304385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
    Yalniz FF; Wierda WG
    Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
    Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
    Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BCL-2-like Proteins to Kill Cancer Cells.
    Cory S; Roberts AW; Colman PM; Adams JM
    Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Apoptosis resistance in malignant tumors: novel apoptosis-based therapeutic approaches].
    Roth W
    Pathologe; 2009 Dec; 30 Suppl 2():113-6. PubMed ID: 19756623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
    Labi V; Grespi F; Baumgartner F; Villunger A
    Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.
    Mason KD; Vandenberg CJ; Scott CL; Wei AH; Cory S; Huang DC; Roberts AW
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17961-6. PubMed ID: 19004807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathways and mechanisms of venetoclax resistance.
    Bose P; Gandhi V; Konopleva M
    Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Apoptosis by the Bcl-2 Family of Proteins: Field on a Brink.
    Ladokhin AS
    Cells; 2020 Sep; 9(9):. PubMed ID: 32961920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
    Merino D; Lok SW; Visvader JE; Lindeman GJ
    Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
    Spender LC; Inman GJ
    Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why anti-Bcl-2 clinical trials fail: a solution.
    Harazono Y; Nakajima K; Raz A
    Cancer Metastasis Rev; 2014 Mar; 33(1):285-94. PubMed ID: 24338002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.
    Trends Cancer; 2016 Oct; 2(10):537-539. PubMed ID: 28741484
    [No Abstract]   [Full Text] [Related]  

  • 20. Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.
    Tian BP; Xia LX; Bao ZQ; Zhang H; Xu ZW; Mao YY; Cao C; Che LQ; Liu JK; Li W; Chen ZH; Ying S; Shen HH
    J Allergy Clin Immunol; 2017 Aug; 140(2):418-430. PubMed ID: 28043871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.